Movement Alert｜Amgen Rises 4.2% in Regular Trading, Q2 Earnings Significantly Beat Expectations with Raised Full-Year Guidance

Market Focus08-05 21:43

On August 5, Amgen rose 4.2% in regular trading, trading at $411.12/share, with turnover of $407 million. The rally was driven by the company's Q2 earnings release, which significantly exceeded market expectations on all key metrics while raising full-year guidance.

Amgen reported Q2 adjusted EPS of $6.29, up 4.49% year-over-year, beating the consensus estimate of $5.62 by nearly 12%. Revenue came in at $10.05 billion versus the $9.43 billion expected. For full-year 2026, the company raised guidance to adjusted EPS of $22.30-$23.50 on revenue of $38.2-$39.4 billion, up from prior guidance of $21.70-$23.10 EPS on $37.1-$38.5 billion revenue. Additionally, the company announced the termination of early-stage obesity drug AMG 513, concentrating resources on MariTide, currently in Phase III trials. Following the report, Morgan Stanley raised its target price to $351, while UBS maintains a $420 target with a Buy rating.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120048666?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 21:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120048666","market":"us","top_or_hot":-1,"title":"Movement Alert｜Amgen Rises 4.2% in Regular Trading, Q2 Earnings Significantly Beat Expectations with Raised Full-Year Guidance","media":"Market Focus","content":"<p><p>On August 5, Amgen rose 4.2% in regular trading, trading at $411.12/share, with turnover of $407 million. The rally was driven by the company's Q2 earnings release, which significantly exceeded market expectations on all key metrics while raising full-year guidance.</p><p>Amgen reported Q2 adjusted EPS of $6.29, up 4.49% year-over-year, beating the consensus estimate of $5.62 by nearly 12%. Revenue came in at $10.05 billion versus the $9.43 billion expected. For full-year 2026, the company raised guidance to adjusted EPS of $22.30-$23.50 on revenue of $38.2-$39.4 billion, up from prior guidance of $21.70-$23.10 EPS on $37.1-$38.5 billion revenue. Additionally, the company announced the termination of early-stage obesity drug AMG 513, concentrating resources on MariTide, currently in Phase III trials. Following the report, Morgan Stanley raised its target price to $351, while UBS maintains a $420 target with a Buy rating.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Amgen Rises 4.2% in Regular Trading, Q2 Earnings Significantly Beat Expectations with Raised Full-Year Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Amgen Rises 4.2% in Regular Trading, Q2 Earnings Significantly Beat Expectations with Raised Full-Year Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-05 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 5, Amgen rose 4.2% in regular trading, trading at $411.12/share, with turnover of $407 million. The rally was driven by the company's Q2 earnings release, which significantly exceeded market expectations on all key metrics while raising full-year guidance.</p><p>Amgen reported Q2 adjusted EPS of $6.29, up 4.49% year-over-year, beating the consensus estimate of $5.62 by nearly 12%. Revenue came in at $10.05 billion versus the $9.43 billion expected. For full-year 2026, the company raised guidance to adjusted EPS of $22.30-$23.50 on revenue of $38.2-$39.4 billion, up from prior guidance of $21.70-$23.10 EPS on $37.1-$38.5 billion revenue. Additionally, the company announced the termination of early-stage obesity drug AMG 513, concentrating resources on MariTide, currently in Phase III trials. Following the report, Morgan Stanley raised its target price to $351, while UBS maintains a $420 target with a Buy rating.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMGN","symbol_name":"安进","start_time":0,"source_url":"","article_id":"1120048666","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120048666","pubTimestamp":1785937406,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 5, Amgen rose 4.2% in regular trading, trading at $411.12/share, with turnover of $407 million. The rally was driven by the company's Q2 earnings release, which significantly exceeded...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMGN":"安进"},"translate_title":"走势警报|安进常规交易上涨 4.2%，第二季度盈利大幅超出预期，全年指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1},"content_text":"On August 5, Amgen rose 4.2% in regular trading, trading at $411.12/share, with turnover of $407 million. The rally was driven by the company's Q2 earnings release, which significantly exceeded market expectations on all key metrics while raising full-year guidance.Amgen reported Q2 adjusted EPS of $6.29, up 4.49% year-over-year, beating the consensus estimate of $5.62 by nearly 12%. Revenue came in at $10.05 billion versus the $9.43 billion expected. For full-year 2026, the company raised guidance to adjusted EPS of $22.30-$23.50 on revenue of $38.2-$39.4 billion, up from prior guidance of $21.70-$23.10 EPS on $37.1-$38.5 billion revenue. Additionally, the company announced the termination of early-stage obesity drug AMG 513, concentrating resources on MariTide, currently in Phase III trials. Following the report, Morgan Stanley raised its target price to $351, while UBS maintains a $420 target with a Buy rating.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120048666","isCrawlerRequest":true}